NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD
Overall LYRA gets a fundamental rating of 3 out of 10. We evaluated LYRA against 195 industry peers in the Pharmaceuticals industry. While LYRA has a great health rating, there are worries on its profitability. While showing a medium growth rate, LYRA is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -141.22% | ||
ROE | -2053.98% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 5.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.96 | ||
Quick Ratio | 2.96 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
18.42
-5.86 (-24.14%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1030.12 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 315.26 | ||
P/tB | 315.26 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -141.22% | ||
ROE | -2053.98% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.96 | ||
Quick Ratio | 2.96 | ||
Altman-Z | 5.99 |